Tech Company Financing Transactions

Versartis Funding Round

Sofinnova Ventures, Advent Venture Partners and Aisling Capital joined a $20 million Series D funding round for Versartis. The round closed on 10/8/2013.

Transaction Overview

Company Name
Versartis
Announced On
10/8/2013
Transaction Type
Venture Equity
Amount
$20,000,000
Round
Series D
Investors

Sofinnova Ventures (Lead Investor) (Srinivas Akkaraju)

Advent Venture Partners (Shahzad Malik)

Aisling Capital (Anthony Sun)

Amunix

Index Ventures (Kevin Johnson)

New Leaf Venture Partners (Michael Dybbs)

Proceeds Purpose
The proceeds from this financing will primarily be used to prepare for an international Phase 3 pediatric trial of VRS-317, the company's proprietary long-acting recombinant human growth hormone (rhGH) for the treatment of growth hormone deficiency (GHD).

Company Information

Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
275 Shoreline Dr. 450
Mountain View, CA 94065
USA
Phone
650-963-8580
Website
www.versartis.com
Email Address
[email protected]
Overview
Versartis (NASDAQ: VSAR) is developing new therapeutic proteins utilizing the novel half-life extension technology, XTEN. Versartis has licensed the rights to three products (VRS-826, VRS-859, and VRS-317) from Amunix.
Profile
Versartis LinkedIn Company Profile
Social Media
Versartis Company Twitter Account
Company News
Versartis News
Facebook
Versartis on Facebook
YouTube
Versartis on YouTube

Management Team

Title
Name
Email & Social
Chief Executive Officer
Jay Shepard
  Jay Shepard LinkedIn Profile  Jay Shepard Twitter Account  Jay Shepard News  Jay Shepard on Facebook
Chief Financial Officer
Joshua Brumm
  Joshua Brumm LinkedIn Profile  Joshua Brumm Twitter Account  Joshua Brumm News  Joshua Brumm on Facebook
Chief Medical Officer
George Bright
  George Bright LinkedIn Profile  George Bright Twitter Account  George Bright News  George Bright on Facebook
VP - Bus. Development
Paul Westberg
  Paul Westberg LinkedIn Profile  Paul Westberg Twitter Account  Paul Westberg News  Paul Westberg on Facebook
VP - Manufacturing
Patrick Murphy
  Patrick Murphy LinkedIn Profile  Patrick Murphy Twitter Account  Patrick Murphy News  Patrick Murphy on Facebook
VP - Operations
Eric Humphriss
  Eric Humphriss LinkedIn Profile  Eric Humphriss Twitter Account  Eric Humphriss News  Eric Humphriss on Facebook
VP - Product Management
Rajendra Mohabir
  Rajendra Mohabir LinkedIn Profile  Rajendra Mohabir Twitter Account  Rajendra Mohabir News  Rajendra Mohabir on Facebook

 

 

Browse more venture capital transactions:

Prev: 10/8/2013: PharmAkea Therapeutics venture capital transaction
Next: 10/8/2013: Shyp venture capital transaction

 

Share this article

 

About Our Venture Capital Transactions Database

We do our best to report on all VC transactions involving tech companies. All VC database entries on this site are sourced from news reports and company announcements. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.

 

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary

 

Copyright © 2001-2024. Gaebler Ventures. All rights reserved.